Attention Deficit Hyperactivity Disorder Market- Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Attention Deficit Hyperactivity Disorder Market is Segmented by Drug Type (Stimulant, Non-stimulant), Age (Adult (Aged 18 and above), Children), Distribution (Retail Pharmacy, Hospital Pharmacy), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.

Market Snapshot

attention deficit hyperactivity disorder market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: Asia-Pacific
CAGR: 6.9 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The attention deficit hyperactivity disorder market is expected to grow at the registered CAGR of 6.9% during the forecast period, 2022-2027.

The attention deficit hyperactivity disorder (ADHD) market is significantly impacted as a result of the COVID-19 pandemic. Governments from various countries are taking steps to combat attention deficit hyperactivity disorder (ADHD) in children. According to the study titled "Behavioral Implications of the Covid-19 Process for Autism Spectrum Disorder, and Individuals' Comprehension of and Reactions to the Pandemic Conditions," published in the Frontier in Psychiatry in November 2020, during the Covid-19 outbreak, symptoms of children with attention deficit hyperactivity disorder (ADHD) worsened significantly. Due to the stress caused by the COVID-19 pandemic, patients with attention deficit hyperactivity disorder (ADHD) have become more vulnerable. Thus, the attention deficit hyperactivity disorder market is significantly impacted by COVID-19.

During the forecast period, the global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to grow due to an increase in the prevalence of the disorder. For instance, as per a February 2021 published study titled, "The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis," the prevalence of persistent adult ADHD was 2.58%, and that of symptomatic adult ADHD was 6.76%, translating to 139.84 million and 366.33 million affected adults in 2020 globally. Thus, rising in the burden of ADHD is expected to rise in demand for its treatment anticipated to boost the market over the forecast period.

Furthermore, the growing emphasis on research and development is resulting in the development of effective ADHD treatments, which is contributing to market growth. For instance, according to the study titled "Neurofunctional and behavioral measures associated with fMRI-Neurofeedback learning in adolescents with Attention-Deficit/Hyperactivity Disorder," published in the NeuroImage Clinical in May 2020, a larger trial with 100 children with ADHD was funded by the Medical Research Council for GBP 1.3 million. New collaborations with the National Institute of Mental Health and Dresden University were also formed as a result of the work. Since then, the team has received funding (roughly GBP 2 million from the National Institute for Health Research, Action Medical Research) to test other brain-based therapies in ADHD, including non-invasive brain stimulation treatments like transcranial direct current stimulation and stimulation of the trigeminal nerve, which controls facial sensations. Such a development in a treatment option for ADHD treatment is expected to boost the market over the forecast period.

The ADHD market is expected to grow due to a rise in public awareness about mental health and increased government funding. The rising number of people suffering from a variety of mental health disorders, including attention-deficit/hyperactivity disorder (ADHD), has drawn the attention of governments all over the world, forcing them to take action. As per the Regional Development Australia updates in July 2021, in 2021-22, the New South Wales (NSW) Government has contributed USD 1.8 million in funding for the ADHD pilot program, with a total investment of USD 7.7 million for the trial a new model of care and management for children with behavioral issues including attention-deficit hyperactivity disorder (ADHD) in regional NSW over four years.

Moreover, during the forecast period, key companies focusing on research and development in the treatment of attention deficit hyperactivity disorder (ADHD) therapeutics are expected to drive the global attention deficit hyperactivity disorder (ADHD) therapeutics market. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a subsidiary in the United States, reported positive top-line results from phase 3 clinical trials evaluating the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.

Thus, the aforementioned factors are likely to drive the growth of the market during the forecast period. However, less availability of non-stimulant ADHD drugs and underdiagnosis of ADHD. Thus, these factors act as some of the major restraints to the studied market.

Scope of the Report

As per the scope of the report, Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders that primarily affects children. ADHD is often diagnosed in childhood and persists into adulthood. Children with ADHD may daydream excessively, forget or lose things, have difficulty resisting temptation, have trouble taking turns, have difficulty getting along with others, be overly active, and have difficulty paying attention. The attention deficit hyperactivity disorder market is segmented by drug type (stimulant, non-stimulant), age (adult (aged 18 and above), children), distribution (retail pharmacy, hospital pharmacy), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Type
Stimulant
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine dimesylate
Non Stimulant
Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age
Adult (Aged 18 and above)
Children
By Distribution Channel
Retail Pharmacy
Hospital Pharmacy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Stimulant Drug Type Segment is Expected to Projected Significant Growth Over the Forecast Period.

The stimulant segment dominated the ADHD market and is expected to continue to do so throughout the forecast period. This is due to the high demand for these drugs, which stems from their efficacy in treating symptoms of attention deficit hyperactivity disorder, ongoing clinical trials, and government support for the use of stimulants in the treatment of mental health disorders. Stimulant drugs include Amphetamine, Methylphenidate, Lisdexamfetamine, and Dexmethylphenidate.

Amphetamines (e.g., Adderall) and methylphenidate (e.g., Ritalin and Concerta) are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder (ADHD). The study titled "A cognitive neuroscience review of the etiology of ADHD," published by the Association of Child and Adolescent Mental Health in January 2022, describe that stimulant works quickly, and there is also a reduction in overall impulsivity and ADHD symptoms in two hours. It also reported that stimulants are the most effective treatment for ADHD patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of ADHD boosts the segment growth over the forecast period.

Furthermore, a rise in clinical studies to evaluate the effectiveness of the stimulant drug in ADHD treatment is anticipated to drive the segment over the forecast period. For instance, as per the ClinicalTrial.gov updates on July 2021, the study titled "A Pivotal Efficacy Trial to Evaluate HLD200 (methylphenidate) in Children With ADHD in a Classroom Setting" under the development phase III by Ironshore Pharmaceuticals and Development, Inc. Hence, the increase in the number of drug development will be expected to increase in the accessibility of ADHD therapeutics and thus anticipated to boost the segment growth.

Moreover, the approval and commercialization of new drugs by market players are also expected to play a crucial role in driving market growth over the coming years. For instance, in March 2021, Azstarys (KemPharma) received Food and Drug Administration approval for a central nervous system stimulant for the treatment of ADHD. It is one of the first drugs with the combination of dexmethylphenidate and serdexmethylphenidate. Such approvals are propelling the growth of the market segment.

Thus, the aforementioned factors are likely to drive the growth of the segment during the forecast period.

 attention deficit hyperactivity disorder market share

North America Holds a Significant Share in the Market and Do the Same during the Forecast Period

North America dominates the ADHD market over the forecast period. This is due to the large number of drug prescriptions written each year, the increased number of product launches, and the increased collaboration among players to improve market penetration and product development.

Furthermore, rising in the prevalence of ADHD in the country is anticipated to drive the market over the forecast period. According to the Centers for Diseases Control and Prevention, in September 2021, 8.8% of people have been diagnosed with ADHD at some point in their lives. Moreover, 13.6 million visits to doctors' offices were made with attention deficit disorder as the primary diagnosis.

In addition, increasing spending on the treatment of ADHD in the United States with rising prescription rates is expected to boost the market. According to the study titled "Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective," published in the Managed Care and Specialty Pharmacy in February 2022, in the United States, an estimated 8,716,972 adults have ADHD, resulting in a total societal excess cost of USD 122.8 billion (USD 14,092 per adult). Thus rise in healthcare spending is anticipated to drive the market growth over the forecast period.

Additionally, approval and commercialization of new drugs are also expected to play a key role in driving market growth in the coming years. For instance, in April 2021, the Food and Drug Administration approved Qelbree (KELL'-bree for treating attention deficit hyperactivity disorder in children ages 6 to 17.

Furthermore, in February 2021, Noven Pharmaceuticals Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) for patients six years and older.

Thus, the aforementioned factors are likely to drive the growth of the marker during the forecast period.

attention deficit hyperactivity disorder market report

Competitive Landscape

The attention deficit hyperactivity disorder market is moderately competitive owing to the presence of multiple players. The players in the market are adopting strategies like product innovation, mergers, and acquisitions in order to expand their product portfolio and expand their geographic reach and primarily to stay competitive in the market. Some of the vendors in the market are Eli Lily & Company, Pfizer, Johnson & Johnson Services LLC, Lupin, Shire, Mallinckrodt, Prude Pharma L.P., and NEOS Therapeutics Inc.

Recent Developments

  • In March 2022, Neos Therapeutics reported the United States release of Adzenys XR-ODT, the first orally disintegrating medication for the treatment of ADHD in patients 6 and older.
  • In February 2022, Noven received Food and Drug Administration approval for Xelstrym (dextroamphetamine) transdermal system for the treatment of attention-deficit/hyperactivity disorder (ADHD) for adults and pediatric patients 6 years and older.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden Of ADHD

      2. 4.2.2 Increasing Awareness Regarding ADHD Among Physicians and Patients

    3. 4.3 Market Restraints

      1. 4.3.1 Underdiagnosis Of ADHD

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Drug Type

      1. 5.1.1 Stimulant

        1. 5.1.1.1 Amphetamine

        2. 5.1.1.2 Methylphenidate

        3. 5.1.1.3 Dextroamphetamine

        4. 5.1.1.4 Dexmethylphenidate

        5. 5.1.1.5 Lisdexamfetamine dimesylate

      2. 5.1.2 Non Stimulant

        1. 5.1.2.1 Atomoxetine

        2. 5.1.2.2 Bupropion

        3. 5.1.2.3 Guanfacine

        4. 5.1.2.4 Clonidine

    2. 5.2 By Age

      1. 5.2.1 Adult (Aged 18 and above)

      2. 5.2.2 Children

    3. 5.3 By Distribution Channel

      1. 5.3.1 Retail Pharmacy

      2. 5.3.2 Hospital Pharmacy

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Eli Lily & Company

      2. 6.1.2 Pfizer

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 Lupin

      5. 6.1.5 Takeda Pharmaceutical (Shire PLC)

      6. 6.1.6 Mallinckrodt

      7. 6.1.7 Perdue Pharma L.P. (Adlon Therapeutics)

      8. 6.1.8 NEOS Therapeutics Inc.

      9. 6.1.9 KemPharm Inc.

      10. 6.1.10 Novartis AG

      11. 6.1.11 Aurobindo pharma

      12. 6.1.12 Otsuka Group

      13. 6.1.13 Hisamitsu Group (Noven Pharmaceutical Inc.)

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Attention Deficit Hyperactivity Disorder Market market is studied from 2019 - 2027.

The Global Attention Deficit Hyperactivity Disorder Market is growing at a CAGR of 6.9% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia-Pacific holds highest share in 2021.

Eli Lily & Company, Pfizer, Lupin, Mallinckrodt , Purdue Pharma L.P are the major companies operating in Global Attention Deficit Hyperactivity Disorder Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!